Literature DB >> 1591217

Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.

P J Openshaw1, S L Clarke, F M Record.   

Abstract

To investigate the contribution of immunity to individual respiratory syncytial (RS) virus proteins to the augmentation of pulmonary pathology, mice were scarified with recombinant vaccinia viruses (rVV) expressing individual RS virus proteins. The pulmonary response to infection with RS virus was monitored by bronchoalveolar lavage (BAL). In mice vaccinated with the major surface glycoprotein (G), 14-25% of BAL cells were eosinophils; these comprised less than 3% of BAL cells from other groups of mice after RS virus challenge. Mice sensitized to the G or fusion (F) proteins developed lung haemorrhage and those sensitized to G, F or nucleoprotein (N) showed pulmonary polymorphonucleocyte efflux. To investigate the concomitant changes in local T-cell subsets, BAL cells were stained with mAbs to CD4, CD8, CD45RB, alpha beta and gamma delta T cell receptor (TCR) proteins. Three colour flow cytometry showed that most cells were CD3+CD4+ alpha beta+gamma delta+ or CD3+CD8+ alpha beta+gamma delta-, although some CD4-CD8-SIg- cells were also identified. Most of these 'null' cells lacked CD3, but CD3+ null cells from rVV-G or -F primed mice bore either alpha beta and gamma delta TCR in approximately equal numbers. The intensity of staining for CD45RB declined rapidly after infection with RS virus on both CD4 and CD8 cells. The rate of loss of CD45RB on CD4 T cells was accelerated by prior sensitization with rVV-G, consistent with conversion to helper T cell subsets producing eosinophil-promoting cytokines. The eosinophilic reaction to RS virus infection therefore specifically reflects sensitization to G protein, but sensitization to other proteins can also cause distinct pathological effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1591217     DOI: 10.1093/intimm/4.4.493

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  86 in total

1.  Immunological responses to respiratory syncytial virus infection in infancy.

Authors:  R L Smyth; J N Fletcher; H M Thomas; C A Hart
Journal:  Arch Dis Child       Date:  1997-03       Impact factor: 3.791

2.  Characterization of human metapneumovirus infection of myeloid dendritic cells.

Authors:  Maria C Tan; Lorenzo Battini; Ana C Tuyama; Salvador Macip; Guillermina A Melendi; Maria-Arantxa Horga; G Luca Gusella
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

Review 3.  Recent vaccine development for human metapneumovirus.

Authors:  J Ren; T Phan; X Bao
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

4.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 5.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

6.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.

Authors:  Whitney W Stevens; Taeg S Kim; Lindsey M Pujanauski; Xueli Hao; Thomas J Braciale
Journal:  J Immunol Methods       Date:  2007-08-08       Impact factor: 2.303

8.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

9.  CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells.

Authors:  W H Alwan; F M Record; P J Openshaw
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

10.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.